Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
39
PHMMF Quote, Financials, Valuation and Earnings
Last price:
$86.26
Seasonality move
:
23.38%
Day range:
$86.26 - $86.26
52-week range:
$80.91 - $110.40
Dividend yield:
0%
P/E ratio:
40.48x
P/S ratio:
7.64x
P/B ratio:
6.38x
Volume:
110
Avg. volume:
54
1-year change:
6.4%
Market cap:
$1.5B
Revenue:
$189.1M
EPS (TTM):
$2.13
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Pharma Mar SA has -- downside to fair value with a price target of -- per share.
PHMMF vs. S&P 500
-
Over the past 5 trading days, Pharma Mar SA has underperformed the S&P 500 by -0.1% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Pharma Mar SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pharma Mar SA revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Pharma Mar SA reported revenues of $41.7M.
Earnings Growth
-
Pharma Mar SA earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Pharma Mar SA reported earnings per share of -$0.27.
Enterprise value:
1.4B
EV / Invested capital:
--
Price / LTM sales:
7.64x
EV / EBIT:
409.27x
EV / Revenue:
6.90x
PEG ratio (5yr expected):
0.01x
EV / Free cash flow:
69.03x
Price / Operating cash flow:
76.40x
Enterprise value / EBITDA:
111.02x
Gross Profit (TTM):
$182.7M
Return On Assets:
9.84%
Net Income Margin (TTM):
18.92%
Return On Equity:
17.03%
Return On Invested Capital:
13.5%
Operating Margin:
-17.3%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $183.5M | $181.1M | $198.1M | $50.2M | $41.7M | |
| Gross Profit | $169.4M | $171M | $182.7M | $47.9M | $36.6M | |
| Operating Income | $513.6K | -$6.1M | $3.3M | $5.6M | -$7.2M | |
| EBITDA | $7.2M | $588.5K | $12.3M | $7.3M | -$4.9M | |
| Diluted EPS | $0.82 | $0.04 | $2.13 | $0.24 | -$0.27 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $325.6M | -- | $276.3M | $265.6M | $285.4M | |
| Total Assets | $403M | -- | $369.9M | $371.8M | $401.5M | |
| Current Liabilities | $94.4M | -- | $91.7M | $99.8M | $104.5M | |
| Total Liabilities | $237M | -- | $151.6M | $168.5M | $164.3M | |
| Total Equity | $166M | -- | $218.3M | $203.3M | $232.1M | |
| Total Debt | $63.2M | $39.2M | $32.6M | $48.7M | $46.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | $2M | $24.5M | $4.7M | $19.6M | |
| Cash From Investing | -- | -$19.3M | $19.4M | $1M | $14.6M | |
| Cash From Financing | -- | -$16.9M | -$29M | $11.8M | -$3.3M | |
| Free Cash Flow | -- | -$19M | $19.8M | $600.9K | $18.1M | |
PHMMF
Sector
Market Cap
$1.5B
$27.9M
Price % of 52-Week High
78.13%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
1.05%
-1.49%
1-Year Price Total Return
6.4%
-16.66%
Beta (5-Year)
0.498
0.516
Dividend yield:
0%
Annualized payout:
$0.70
Payout ratio:
-33.19%
Growth streak:
2 years
Technicals
8-day SMA
Sell
Level
$86.26
200-day SMA
Sell
Level
$93.49
Bollinger Bands (100)
Sell
Level
87.96 - 99.42
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$86.32
Relative Strength Index (RSI14)
Sell
Level
19.28
ADX Line
Neutral
Level
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$89.75
MACD (12, 26)
Buy
Level
16.22
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.6733)
Buy
CA Score
(Annual)
Level (0.14)
Sell
Beneish M-Score
(Annual)
Level (-2.0073)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-1.1146)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It operates through the following segments: Oncology, Diagnostics, and RNAi. The Oncology segment focuses to the group undertakings whose object is to research, develop, and market anti-tumour drugs. The Diagnostics segment focuses in the development and marketing of diagnostic kits. The RNAi segment develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was founded by José Maria Fernández de Sousa-Faro on April 30, 1986 and is headquartered in Colmenar Viejo, Spain.
Stock Forecast FAQ
In the current month, PHMMF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PHMMF average analyst price target in the past 3 months is --.
-
Where Will Pharma Mar SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pharma Mar SA share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Pharma Mar SA?
Analysts are divided on their view about Pharma Mar SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pharma Mar SA is a Sell and believe this share price will rise from its current level to --.
-
What Is Pharma Mar SA's Price Target?
The price target for Pharma Mar SA over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PHMMF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pharma Mar SA is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of PHMMF?
You can purchase shares of Pharma Mar SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pharma Mar SA shares.
-
What Is The Pharma Mar SA Share Price Today?
Pharma Mar SA was last trading at $86.26 per share. This represents the most recent stock quote for Pharma Mar SA. Yesterday, Pharma Mar SA closed at $86.26 per share.
-
How To Buy Pharma Mar SA Stock Online?
In order to purchase Pharma Mar SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get PHMMF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PHMMF
Sector
P/E ratio
40.48x
23.85x
PEG ratio
0.01x
-0.01x
P/B ratio
6.38x
1.81x
Price / LTM sales
7.64x
1.58x
Growth Metrics
PHMMF
Sector
Revenue growth
-16.91%
4.62%
Earnings growth
-213.04%
10.5%
Revenue (5-year growth)
14.51%
6.5%
Earnings forecast
--
-$0.21
Profitability
PHMMF
Sector
Profitability FY 2024
$173M
$3.6M
Return on invested capital
13.5%
-31.87%
Return on assets
9.84%
-28.18%
Return on equity
17.03%
-37.63%
Earnings Date
Last Earnings Date
Oct
30
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Jan
29
Balance Sheet
PHMMF
Sector
Total cash
$172.3M
$26.4M
Short term investments
$95M
$25.7M
Total assets
$362.5M
$76.9M
Long term debt
$46.3M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
